SEED Therapeutics, A Subsidiary Of BeyondSpring, Discloses Novel Molecular Glue IND Candidate For Cancer At "Targeted Protein Degradation Think Tank" Symposium
Portfolio Pulse from Benzinga Newsdesk
SEED Therapeutics, a subsidiary of BeyondSpring (NASDAQ:BYSI), announced the discovery of a new molecular glue, ST-00937, for cancer treatment. The new chemical entity has achieved IND Candidate status and is expected to be advanced for cancer treatment in SEED's first IND filing as early as 2024. The announcement was made at the Targeted Protein Degradation (TPD) Think Tank symposium, where SEED's research and development scientists recognized the opportunity to discover additional indications for an RBM39 targeted molecular glue.
October 26, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BeyondSpring's subsidiary, SEED Therapeutics, has discovered a new molecular glue for cancer treatment. This could potentially lead to a new product in BeyondSpring's pipeline, which could positively impact its stock price.
The discovery of a new molecular glue for cancer treatment by SEED Therapeutics, a subsidiary of BeyondSpring, could potentially lead to a new product in BeyondSpring's pipeline. This could increase the company's revenues in the future, which would likely have a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100